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The hepatitis C virus NS5A protein is an established and clinically validated target for antiviral
intervention by small molecules. Characterizations are presented of compounds identiﬁed as potent
inhibitors of HCV replication to provide insight into structural elements that interact with the NS5A
protein. UV-activated cross linking and afﬁnity isolation was performed with one series to probe the
physical interaction between the inhibitors and the NS5A protein expressed in HCV replicon cells.
Resistance mapping with the second series was used to determine the functional impact of speciﬁc
inhibitor subdomains on the interaction with NS5A. The data provide evidence for a direct high-afﬁnity
interaction between these inhibitors and the NS5A protein, with the interaction dependent on inhibitor
stereochemistry. The functional data supports a model of inhibition that implicates inhibitor binding by
covalently combining distinct pharmacophores across an NS5A dimer interface to achieve maximal
inhibition of HCV replication.
& 2013 Elsevier Inc. All rights reserved.Introduction
Chronic hepatitis C virus infection remains an important area of
unmet medical need requiring the continued search for assays to
ﬁnd speciﬁc and effective inhibitors. Cell-based hepatitis C virus
(HCV) replication assays provide many advantages that traditional
enzymatic assays lack or have difﬁculty duplicating. Capturing the
entire replication cycle using cells based assays can probe for
inhibitors that can target enzymatic function or mechanisms more
elusive in nature such as transient associations of biomolecules or
the capturing of unique conformations. These transient functions
can represent essential processes involved in virus replication that
cannot readily be duplicated in vitro (Sun et al., 2003; Sheaffer
et al., 2008; Holler et al., 2009). The use of cell-based HCV replicon
screens has allowed the discovery of a number of small molecule
inhibitors that implicate viral proteins with no known enzymatic
function as targets, including NS4B and NS5A (MacDonald and
Harris, 2004; Conte et al., 2009; Green et al., 2008; Einav et al.,
2008; Shotwell et al., 2012). Problematically, the replication of
viruses can be quite sensitive to effects that are off-target from all rights reserved.
).speciﬁc virus function possibly affecting a cell process(es) required
for replication or normal cell maintenance; thus a screening “hit”
could simply reﬂect cell toxicity. The multiplexed design for
antiviral screening represents a more ideal situation in that
multiple readouts can be used to prioritize inhibitors with higher
conﬁdence of speciﬁcity. This type of cell-based approach using a
cost effective multiplexed assay has been used to identify a series
of compounds at Bristol-Myers Squibb with modest initial potency
whose resistance changes were mapped to the NS5A protein of
HCV (O’Boyle et al., 2005; Lemm et al., 2010, 2011; Gao et al., 2009;
Romine et al., 2011). The amino acid changes resulting in com-
pound resistance were demonstrated to be caused by substitutions
at amino acids L31, Q54 and Y93 in NS5A. Using a model of the
NS5A Domain 1 crystal structure (Love et al., 2009; Tellinghuisen
et al., 2005), these changes have been determined to lie at a dimer
interface of NS5A. The inhibitors are hypothesized to disrupt an
essential NS5A function(s) that relies upon dimer formation
required for replication. This suggests that the function(s) of
NS5A, beyond its known involvement in packaging of the viral
genome (Tellinghuisen et al., 2008a; Lindenbach et al., 2005;
Appel et al., 2005a), are likely to be more diverse than originally
contemplated and that different forms of NS5A, i.e. -phosphory-
lated and/or conformationally changed; may perform functions
not readily duplicated in vitro (Huang et al., 2005, 2007; Appel
Fig. 1. Stilbene based compounds used in this study for afﬁnity puriﬁcation and UV activated crosslinking in HCV replicon cells. BMS-346 represents the active lead
compound chosen for use as an afﬁnity reagent in the series due to the potency of the un-modiﬁed compound. BMS-671 and BMS-690 represent the biotinylated 5A
compounds used in afﬁnity puriﬁcation that differ only in stereochemistry. BMS-194 and BMS-350 contain UV reactive azide groups, while BMS-350 also includes a biotin
moiety. BMS-351 contains 2 UV reactive (Bis-azide) groups. The associated EC50 and CC50 values are listed for each compound. EC50¼concentration of compound resulting in
50% HCV FRET activity when compared to DMSO control. CC50¼concentration of compound resulting in 50% reduction of Alamar blue conversion when compared to DMSO
control.
D.R. O'Boyle II et al. / Virology 444 (2013) 343–354344et al., 2005b; Evans et al., 2004; Kim et al., 1999; Reed et al., 1997;
Tellinghuisen et al., 2007, 2008b; Fridell et al., 2011b).
Recent publications clearly demonstrate the utility of HCV
NS5A inhibitors, validating this approach as a clinically-relevant
target, proven effective and potent in suppressing viral replication
in HCV-infected subjects (Nettles et al., 2008; Gao et al., 2008,
2010; Asselah, 2010). The development of HCV NS5A inhibitors
required extensive optimization of the original lead structure
which proved to be cryptic in nature (Lemm et al., 2011 and
reviewed in Belda and Targett-Adams, 2012). This enterprise
resulted in the synthesis of a wide range of analogs designed to
probe different aspects of the pharmacophore, optimize for broad
genotype inhibition and build in properties commensurate with
oral bioavailability (O’Boyle et al., 2005; Nettles et al., 2008; Gao
et al., 2008, 2010; Bristol-Myers Squibb, 2004, 2007, 2008a, 2008b,
2008c; Gao et al.; Lemm et al., 2011; Romine et al., 2011). This
compound estate provided molecules with a wide range of
virological properties, several of which presented as useful tools
with which to probe aspects of NS5A function and drug–target
interactions. This report will focus on a small subset of compounds
which were chosen for exploration as pharmacophore probes and
for use as afﬁnity reagents to characterize interactions with the
HCV NS5A protein. The compounds are demonstrated to bind to
NS5A with high afﬁnity and speciﬁcity with evidence supporting
binding via NS5A protein dimers. The use of compounds repre-
senting truncated versions of the larger, symmetrical inhibitor
pharmacophore, characterized by daclatasvir, provides further
evidence of direct and speciﬁc interactions occurring between
the NS5A protein and this compound class. These compounds
demonstrate an ability to separate dual-linked NS5A resistance
changes (L31V and Y93H) into individual changes usingsubstructures of the pharmacophores present within the symme-
trical inhibitor chemotype. The results suggest that a speciﬁc
interaction occurs between the NS5A protein and discrete struc-
tural elements of the individual compounds which, when united
into a single, symmetrical molecule, can greatly enhance antiviral
potency.Results
Previous resistance mapping of HCV replication inhibitors
discovered at Bristol-Myers-Squibb indicated that the compounds
target the HCV NS5A protein as indicated by resistance substitu-
tions at amino acid leucine 31 to valine (L31V) and, tyrosine 93 to
histidine (Y93H) as well as others (Lemm et al., 2010; Gao et al.,
2008, 2010). Medicinal chemistry efforts to optimize the potency
and in vitro proﬁle of the inhibitors generated multiple chemo-
types, a subset of which have been used to test for direct
interactions with the NS5A protein. The parent compound selected
for modiﬁcation, BMS-346 (EC50∼100 pM), is a potent inhibitor of
HCV genotype 1b (gt1b) replication. The BMS-346 scaffold was
modiﬁed to introduce afﬁnity or cross-linking groups to determine
if the modiﬁed compounds would: (i) retain inhibitory activity and
(ii) be useful as probes for NS5A protein isolation. This compound
and related stilbene-based NS5A inhibitors used in these studies
are shown in Fig. 1 along with their HCV replicon inhibitory
activities. The changes required to generate afﬁnity probes
reduced the activity by ∼28–1600-fold but, because of the high
inherent potency of the prototype molecule, still yielded active
compounds with EC50 values ranging from 7 to 400 nM. As shown
in Fig. 1, the BMS-346 scaffold was modiﬁed to introduce biotin,
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Fig. 2. (A) Detection of compound binding to NS5A protein in both wild-type and resistant cells. 1b cells or 1b NS5A Y93H cells exposed to either BMS-671 (active) or BMS-
690 (inactive) compounds followed by streptavidin afﬁnity puriﬁcation and probing with anti-NS5A antibody suggest at least two modes of binding are possible: productive
(inhibitory) or non-productive (non-inhibitory). Lanes 1 & 2+5 & 6 – Starting fractions, Lanes 3 & 4+7 & 8 – Not bound fractions, Lanes 11 & 12+13 & 14 – Bound Fractions.
671 or 690 above the lanes refers to the compound added to the cells. The bound fractions are the proteins that remained bound to the streptavidin beads following washing
and were eluted using sample buffer at 100 1C. As seen, BMS-671 results in a similar enrichment compared to BMS-690 from both cell types. Huh-7 lysate was run as a
control with only the eluted material shown for both 671 (lane 9) and 690 (lane 10). (B) Starting lysates and bound proteins following exposure of cells to DMSO (Lanes) or
BMS-671 compound (+Lanes) bind to and enrich for NS5A but not NS3. The panel on the left shows the composition of the starting lysate: Rows 1 thru 4 show blotting of the
HCV replicon cell lysate samples and probing with anti-NS3 antibody; the same blot was then stripped and re-probed with anti-NS5A anti-body in lanes 5 thru 8. The arrows
indicate the position where NS3 or NS5A would be expected to migrate through the gel. The proteins are present in both untreated and compound treated cells, with a slight
reduction due to antiviral activity seen in the +columns, indicating BMS-671 added. The lower mw band in lanes 5–8 is due to NS5A proteolysis in the starting samples.
Following binding, the samples were applied to streptavidin beads, followed by extensive washing then eluted with SDS–sample buffer with heating to 100 1C: Rows 9 thru
12 show blotting of the streptavidin beads samples and probing with anti-NS3 antibody; the same blot was then stripped and re-probed with anti-NS5A anti-body as
indicated in lanes 13 thru 16.
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biotin group was considered to be useful as an afﬁnity tag for
isolation of interacting proteins, while the cross-linking function-
ality was anticipated as useful for peptide isolation via covalent
linkage following UV activation. The introduction of biotin to the
stilbene chemotype yielded compound BMS-671 which had some-
what reduced replicon activity (EC50∼100 nM). A diastereomer of
BMS-671, BMS-690 showed greatly reduced activity (43 mM)
when tested on HCV replicon cells. These two compounds are
identical except for the absolute conﬁguration at the proline
moiety and this structure–activity relationship mirrors that
observed with dimeric inhibitors of HCV NS5A. Preliminary
experiments using these afﬁnity probes (BMS-671 and BMS-690)
and NS5A protein expressed in E. coli revealed no evidence of
speciﬁc binding; nor did additional experiments with proteinexpressed in rabbit reticulocyte lysates (data not shown). These
results are in agreement with other studies and suggest an
absolute requirement for compounds to be preincubated with
replicon cells in order to detect speciﬁc compound association
with the NS5A protein (Gao et al., 2010; Targett-Adams et al., 2011;
Lim et al., 2012). Experiments using BMS-671 and BMS-690 in HCV
replicon cells determined previously that an interaction with NS5A
could be detected (Gao et al., 2010; Targett-Adams et al., 2011). To
extend and conﬁrm these results, HCV replicon cells consisting of
either wild-type gt1b (Con-1), a mutant containing the Y93H in
NS5A or Huh-7 cells devoid of replicon were incubated for ∼14 h at
37 1C with the afﬁnity compound probes. Following treatment, the
cells were washed with PBS, and NP-40 buffer was added to
produce a cell lysate. Cell lysates (starting fractions) were incu-
bated with streptavidin beads for 2 h at 4 1C. The beads were
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Fig. 3. NS5A replication complex inhibitors bind non-covalently with high-afﬁnity
to the NS5A protein as shown for the differential release of NS5A protein bound to
biotinylated compound versus biotinylated ﬂourescein following exposure of
streptavidin beads to SDS. The ﬁrst 10 fractions following exposure to SDS buffer
at either 70 1C or 100 1C are shown (10 fractions eluted at 70 1C and 10 fractions
from 100 1C are indicated). The relative amounts of NS5A present in each fraction
was determined by densitometry scanning of a NS5a speciﬁc western (lighter bars)
while Flourescein labeled biotin was monitored via ﬂuorescence (darker bars) as
described in materials and methods. A separation of NS5A protein from strepta-
vidin tagged with ﬂourescein is clearly shown indicating a release of protein from
compound but not release of biotin from streptavidin.
D.R. O'Boyle II et al. / Virology 444 (2013) 343–354346pelleted and washed extensively with NP-40 buffer (not bound
fractions), while proteins bound to the washed beads were eluted
with SDS-PAGE buffer (100 1C). All samples were then fractionated
on a 10% SDS-PAGE gel and the fractionated proteins probed with
an NS5A antibody to reveal speciﬁc enrichment of NS5A for both
wild-type and mutant Y93H NS5A (Fig. 2A). This pattern indicated
that compound BMS-671 is capable of efﬁciently binding to and
enriching HCV NS5A protein from both cell lines with an estimated
∼25–50% efﬁciency, while the diastereomer BMS-690 was less
efﬁciently pulled down. Furthermore, this result suggests that
binding is necessary but not sufﬁcient for inhibition and requires
additional modiﬁcations for inhibitory competency. This is remi-
niscent of modiﬁcations required to impart gt1a activity using
gt1b only inhibitors or to provide additional mutant coverage (Gao
et al., 2011; St. Laurent et al., 2013). Additional experimental
controls, including Huh-7 cells not expressing replicon gave no
enrichment signal as seen in lanes 9 and 10 Fig. 2A; similarly the
non-biotin-containing parent compound, BMS-346, also failed to
enrich NS5A (data not shown).
To further evaluate the speciﬁcity of the afﬁnity selection of
NS5A, DMSO or BMS-671 was added to an equal number of
replicon cells, and a western blot of starting lysates and lysates
eluted from streptavidin beads was probed sequentially with NS3
followed by NS5A antibody. This sequential method ensures that
identical lysates were evaluated for NS3 and NS5A interactions
following afﬁnity enrichment with the biotin arm of the com-
pound. As shown in Fig. 2B, NS5A (lanes 15 and 16) was
signiﬁcantly enriched compared to either the bound fraction of
NS3 protein (lanes 11 and 12) or the NS5A proteins present in the
starting material (lanes 7 and 8). This enrichment pattern indicates
that the active compound BMS-671 speciﬁcally interacts with
NS5A protein and can remain associated with the biotin moiety
during washing of the afﬁnity matrix. The pattern for the inactive
diastereomer BMS-690 was similar to the DMSO treated cells, with
no signiﬁcant binding to NS3, NS5A, or NS5B (data not shown).
Since the presence of the biotinylated inhibitor BMS-671
speciﬁcally enriched for NS5A, a strong association appeared to
exist between the NS5A protein and this compound. However,
it was possible that a reactive compound derivative, not readily
detectable in this system, formed a covalent linkage with NS5A
since speciﬁc binding could only be detected if the compound was
incubated with replicon cells. Therefore, it was considered possible
that incubation at 37 1C in the cellular milieu provided an “activa-
tion” step necessary for binding. Although preliminary experi-
ments suggested that the observed inhibition was reversible (data
not shown), additional experiments were conducted to determine
if covalent linkage occurred. Since the interaction of biotin with
streptavidin is one of the tightest non-covalent interactions known
(Kd∼1015 mol/L), it was anticipated that if the binding of inhi-
bitor to NS5A is high-afﬁnity but non-covalent, it should be
possible to identify conditions that leave biotin–streptavidin
associated while releasing NS5A protein from the compound.
To determine if NS5A binding to BMS-671 is non-covalent, lysates
from HCV replicon cells exposed to BMS-671 were incubated with
streptavidin beads, and washed beads were exposed to conditions
that were contemplated to cause protein unfolding. Multiple
conditions were tested for release of the NS5A protein from the
biotin–streptavidin bead complex, with biotinylated ﬂourescein
used as a control to monitor the retention of biotin by the
streptavidin beads. The release of NS5A from the bead-linked
compound was monitored by western analysis with densitometry,
while the control biotinylated-ﬂourescein was monitored by ﬂuor-
escence. Conditions tested included washes with: (1) Glycine–HCl,
pH¼3.5; (2) 8 M guanidine HCl; (3) 8 M urea; (4) 30% acetonitrile;
(5) 2 M NaCl with 0.5% NP-40; (6) 5% SDS with 25% glycerol; (7) 5% β-
mercapto ethanol; (8) 50 mM Tris–HCl, pH 3 and 10; or (9) SDS–sample buffer at 25 1C and 70 1C (Biorad #161-0737: 62.5 mM Tris–
HCl, pH 6.8, 2% SDS, 25% glycerol, 0.01% Bromophenol Blue). The
elution data indicated that SDS–sample buffer at 70 1C rather than
25 1C would efﬁciently release the NS5A protein while leaving the
biotinylated ﬂourescein bound to the streptavidin beads. The data is
shown for 20 fractions (10 fractions at 70 1C, 10 fractions at 100 1C) in
Fig. 3. The two measurements, one for ﬂourescein and one for NS5A
protein, are shown as bar graphs from individual fractions in Fig. 3.
As shown, the NS5A protein mostly eluted in fractions 70-1 to 70-4
while the biotinylated ﬂourescein remained ﬁrmly associated with
the beads until heating to 100 1C (fraction 100-1). Quantiﬁcation of
the amount of NS5A retained on the beads versus amount of starting
NS5A protein was estimated to be ∼35%, suggesting that the
stoichiometry for the NS5A-compound complex, even at saturating
concentrations of 1 mM used in the experiments, reﬂected an
abundance of non-compound-bound NS5A protein despite 100%
replication inhibition. The small amount of NS5A protein detected
in the 100 1C wash likely represents material trapped in the beads
and was estimated to be o4% of the sample. These data strongly
suggested that the NS5A protein is tightly associated with but not
covalently bound to the compound.
Since the interaction between NS5A and BMS-671 appeared to
be stable under acidic conditions and up to 5% SDS at room
temperature, the samples were subjected to classical immunopre-
cipitation to determine if the interaction between the inhibitor
and NS5A is direct or possibly through a known or unknown
auxiliary protein(s) (Seng-Li, 2006; Tellinghuisen and Rice, 2002).
HCV replicon cells were incubated with BMS-671 or DMSO for
16 h. Lysates from the treated cells were prepared in 2% SDS and
immunoprecipitated with antibodies directed against either NS3
or NS5A. The antibody–antigen interaction was then disrupted
with acidic conditions that were shown previously not to disrupt
the NS5A/inhibitor interaction (condition #1 from elution studies)
and the antibody-conjugated beads were removed by centrifuga-
tion, and the buffer neutralized. The neutralized supernatants,
spiked with SDS-PAGE sample buffer (but not heated to retain
bound compound (condition #9 from elution studies)), were
Fig. 5. Immuno-precipitation and detection of NS3 and NS5A by chemilumines-
cence and autoradiography using the radiolabeled NS5A inhibitor BMS-194
demonstrates compound NS5A binding is not dependent upon biotin. The arrows
indicate where NS3 (left panel) or NS5A (right panel) proteins migrated following
compound exposure as shown in the WB (western blot) lanes versus the AG
(autoradiography) lanes.
D.R. O'Boyle II et al. / Virology 444 (2013) 343–354 347fractionated by SDS-PAGE. Gels were loaded with duplicate alter-
nating samples from cells treated with either DMSO or BMS-671,
transferred to nitrocellulose membranes and then probed with
either NS3 or NS5A antibody, as shown in Fig. 4. The bands
corresponding to NS3 or NS5A were then marked and the
membranes washed free of signal. The same membranes were
then re-probed with biotin antibody. The data indicates that only
the NS5A band co-migrates with a signiﬁcant biotin signal seen in
the compound treated lanes (Fig. 4). This co-migration of protein
and biotin was not detected in samples from DMSO-treated cells
or samples from inhibitor-treated cells immunoprecipitated with
NS3 antibody. These data strongly suggest that the biotin contain-
ing compound co-migrates to this position due to an association
with the NS5A protein, providing evidence for a direct and speciﬁc
interaction between the inhibitor and the HCV NS5A protein.
The afﬁnity selection and immunoprecipitation data suggested
that there is a speciﬁc and direct high-afﬁnity interaction between
NS5A and the inhibitor BMS-671. To address the possibility that
the binding interaction is potentiated by biotin, a related com-
pound, lacking a biotin moiety, was used to test the interaction.
BMS-194 (EC50∼7 nM) is a potent analog of BMS-671 which lacks
biotin but contains an azide group that can be photo-activated by
UV irradiation to afford a reactive nitrene (Fig. 1). A tritium
radiolabel was incorporated into BMS-194 (∼24,000 cpm/pmole)
as a method for detection. HCV replicon cells were exposed to
BMS-194, rinsed in cold PBS and exposed to UV light to enable
activation of the azide cross-linker prior to preparation of cell
lysates. NS5A and NS3 were immunoprecipitated from the lysates,
fractionated by SDS-PAGE under conditions that were shown not
to disrupt the protein–compound interaction, and transferred to
nitrocellulose in duplicate for detection using either chemilumi-
nescence (for protein) or autoradiography (for compound). As
shown in Fig. 5, the arrows indicate the position of the protein
bands corresponding to NS3 or NS5A which were marked on the
membrane after chemiluminescence exposure for HCV protein
detection. The area indicated by arrows show the positions whereFig. 4. Immuno-precipitation and detection of NS3 and NS5A followed by detection
of biotin indicates that biotinylated compound is associated with NS5A protein but
not NS3. The biotin containing active compound, BMS-671 (+ Lanes), or DMSO (
Lanes) was added to HCV replicon cells; soluble lysates made, divided in half and
used for either NS3 or NS5A immunoprecipitation. The arrows indicate the position
of the protein bands corresponding to NS3 or NS5A which were marked after
chemiluminescence exposure of lanes cut from both sides of the membrane.
Following HCV protein detection, the membranes were aligned and marked at
areas corresponding to the HCV proteins and probed for biotin. Biotin-speciﬁc
bands are seen (arrow) at the same position marked by comparison to the
membranes at the NS5A position while the corresponding area for NS3 detects
no signiﬁcant signal for biotin at the position that NS3 was detected.NS5A or NS3 protein would be located. The radio-labeled com-
pound, if present, would be detected by placement of a dried
nitrocellulose membrane in direct contact with photographic ﬁlm.
As shown in Fig. 5, the autoradiogram detects no signiﬁcant signal
for radioactivity at the position that NS3 was detected but contains
a weakly detectable signal at a position where NS5A migrates. This
signal is not dependent upon IP efﬁciency since the amount of NS3
protein present on the membrane (∼313 ng) versus NS5A (∼20 ng)
was determined to be ∼16-fold greater by comparison to a western
standard (data not shown). These data again suggest that the
inhibitor interacts speciﬁcally with the NS5A protein and that the
interaction is not dependent upon biotin.
As depicted in Fig. 1, BMS-350 incorporates both a biotin tag
and a UV activateable azide moiety. Although BMS-350 has
reduced potency and increased cytotoxicity in HCV replicon
assays, speciﬁc inhibition was conﬁrmed by the sensitivity of this
compound to resistance mutations (data not shown). This com-
pound was used to prepare and isolate an NS5A peptide to which
the compound was presumed to interact with since the complex
could be captured by photoactivation of the azide cross-linking
moiety followed by dual afﬁnity selection of ﬁrst the FLAG
epitope for NS5a protein followed by monomeric avidin to capture
the biotin group on the compound. Huh-7 cells expressing a
replication-competent FLAG-tagged NS5A replicon (Gao et al.,
2004) were exposed to BMS-350 overnight followed by washing
with PBS and exposure to UV light. Lysates were prepared and
NS5A protein was enriched as described in the Methods section.
Peptides released from the monomeric avidin beads were
identiﬁed by mass spectroscopy to yield two overlapping pep-
tide fragments consistent with amino acids 21–30 of NS5A
(TWLQSKLLPR). The assignment, based on molecular weight and
not amino acid sequence, identiﬁes a putative binding region for
BMS-350 in domain 1 of NS5A. These data are consistent with the
afﬁnity selection, providing additional evidence that the series of
compounds shown in Fig. 1 interact directly with NS5A. The
binding results are also consistent with previously published
genetic studies that show NS5A inhibitors target the N-terminus
of the protein (Lemm et al., 2010). Furthermore, the peptide cross-
linked to inhibitor is adjacent to leucine 31; substitutions at L31
are associated directly with resistance to compounds in this series
(Lemm et al., 2010; Gao et al., 2008). These data strongly suggest
that the symmetrical compounds shown in Fig. 1 bind avidly,
reversibly and speciﬁcally to the amino terminus of the NS5A
protein.
NS5A has recently been demonstrated to form dimers in vivo
(Lim et al., 2012; Bhattacharya et al., 2012) complementing the
D.R. O'Boyle II et al. / Virology 444 (2013) 343–354348initial dimeric crystal structure of NS5A Domain 1 revealed by
Tellinghuisen and Love (Love et al., 2009; Tellinghuisen et al.,
2005). It has been hypothesized that the symmetrical NS5A
replication complex inhibitors would likely bind to a dimeric form
of the NS5A protein such that a single compound would interactFig. 6. TOP – NS5A speciﬁc western on total cell lysates from cells exposed to HCV
inhibitors provide evidence that NS5A replication complex inhibitors interact with
NS5A protein dimers and possibly higher-order multimers: (1) DMSO, (2) NS3
Inhibitor, (3) BMS-052 (Daclatasvir, DCV), (4) BMS-346 (Parent), (5) BMS-350
(Mono-azide), and (6) BMS-351 (Bis-azide). Lane M are markers with sizes (Kd)
indicated on the gel. The band just above the 100 kDa marker in lane 6 is speciﬁc
for compound BMS-351 only with the red arrow indicating the area expected for an
NS5A dimer. Bottom – Comparison of coomassie stained gel of enriched gt1b FLAG
extracts treated with either DMSO or BMS-351 to westerns for NS5B, NS3 or NS5A
indicating that the afﬁnity tag is accessible following cross-linking of NS5A dimers.
Gels are replicates and consist of Markers (present only in 1st gel),then 7 lanes
consisting of: (1) start – DMSO, (2) not bound-DMSO, (3) eluted –DMSO, (4) Huh-7
cells (non-replicon), (5) Start+351, (6) not bound+351, (7) eluted+351. Red arrows
indicate approximate positions expected for NS5A of N¼1–4.
Fig. 7. Bi-benzyl compound series used for resistance selection with the EC50 and CC50 va
from replication complex inhibitor compound fragments. The fully symmetrical compoun
BMS-407 represents the bi-benzyl series “core” region while BMS-556 was chosen to rep
BMS-411 are highlighted in blue for each compound. Note the loss in potency compared t
compounds compared to non-selected replicon cells. EC50¼concentration of comp
CC50¼concentration of compound resulting in 50% reduction of Alamar blue conversionwith 2 NS5A proteins across the dimer interface. To explore this
possibility, a bis-azido analog of the mono-azide was synthesized
in order to examine if the compound would be capable of
covalently linking the NS5A protein dimers. The joining of
2 NS5A proteins would be detected as a multiple of the mono-
meric NS5A protein with the molecular weight shifted from
56 kDa (N¼1) to ∼112 kDa (N¼2) by western immuno-analysis.
To test this, the bis-azide along with DMSO and control com-
pounds consisting of: BMS-346 (parental compound), BMS-350
(mono-azide), BMS-052 (daclatasvir, DCV) or a NS3 protease
inhibitor asunaprevir (ASV) were added to replicon cells. As shown
in the top of Fig. 6, lane 6, a band corresponding to a dimer (N¼2)
of NS5A is clearly present only in the bis-azide sample lane and is
not detected in any other compound lane containing the crude-cell
lysates. To exclude the formation of NS5A–NS5B and NS5A–NS3
heterodimers, antisera against either NS3 or NS5B was used on
replicate blots that contained samples from either DMSO-treated
cells or BMS-351-treated cells that were processed for enrichment
via the FLAG epitope in the NS5A protein. As seen at the bottom of
Fig. 6, additional higher molecular weight NS5A reactive bands are
present in the bis-azide-treated samples following enrichment
with FLAG beads but are not detected in the DMSO-treated cells.
The NS3 and NS5B antisera can detect their respective HCV
proteins but do not show any speciﬁc reactivity in the NS5A dimer
region even following enrichment or longer exposure (data not
shown). This result demonstrates that the compound can bind and
crosslink NS5A from at least 2 separate NS5A proteins resulting in
the detection of a dimeric NS5A species. The presence of higher
molecular weight species detected with the NS5A antisera in both
the crude cell lysate and enriched lysates may suggest additional
multimer complexes are possible or that the protein is aggregating
non-speciﬁcally. Further experiments are planned to address these
possibilities.
The previous experiments demonstrated that a speciﬁc physical
interaction between NS5A proteins and small molecule inhibitors
could be detected in replicon cells. To further delineate the
interaction between these inhibitors and HCV NS5A in replicon
cells, a genetic approach utilizing resistance characterization was
used to relate changes in inhibitor structure to the interaction with
NS5A. To accomplish this, a select group of compounds on whichlues listed on HCV replicon cells demonstrate the ability to retain inhibitory activity
d, BMS-411 is used for comparison to the less potent compounds listed underneath.
resent the “cap” region of the fully symmetrical series. The regions in common with
o BMS-411 for each compound. Resistance represents the fold-change seen with the
ound resulting in 50% HCV FRET activity when compared to DMSO control.
when compared to DMSO control.
Table 1
A. EC50 values of compounds tested on cells selected with either BMS-556, representing the cap region, or on BMS-407 representing the core region suggest distinct
differences. The individual values indicate all selections resulted in resistance with the most resistance noted for the cap region and the least fold-resistant with the core
region. The observed inhibitory activity for BMS-411 (symmetrical) suggests that the cap and core selected cells contain different mutations since the activities vary on these
selected cells.
Compound type Potency on resistant cells Wild type potency FOLD vs. WT
EC50 selected (μM) EC50 WT (μM)
CAP selected (556)
CAP (556) 23.7 0.04 655
Core (407) 2.6 0.15 18
Symmetrical (411) 2.43E03 1.77E05 136.9
Core selected (407)
Core (407) 5.2 0.15 35.2
CAP (556) 1.6 0.04 44.8
Symmetrical (411) 7.05E05 1.77E05 ∼4.0
B. Sequencing results following RT-PCR and subsequent cloning of PCR products reveal different substitutions: V (6/6)¼Amino acid seen (number of clones with
mutation/total clones sequenced). The cap is shown to be more affected by Y93 changes while the core is more affected by L31 changes. The Q54 amino acid indicated
2 different mutations present as well 1 un-changed (wt) sequence.
Compound selection L31 Q54 Y93
BMS-407 (core) V (6/6) R (3/6), L (2/6) Not detected
BMS-556 (cap) Not detected Not detected H (8/8)
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Fig. 7 shows the replicon activity and resistance proﬁle of 3 NS5A
inhibitors used for analysis on both wild-type and a double
resistant cell line containing the linked substitutions at amino
acids L31 and Y93 of NS5A. DCV is listed for comparison at the
bottom of Fig. 7. Inspection of the potencies on either the wild-
type or mutant cells indicates that BMS-411, like DCV, retains
nanomolar activity toward the LVYH replicon cells. The less potent
inhibitors (BMS-407 and 556), which incorporate pharmacophoric
elements present in all of the compounds (highlighted in blue in
Fig. 7), are inactive on the LVYH cells at the concentrations tested.
These data indicate that the replicon inhibition observed is NS5A-
speciﬁc for each compound, although the potency varies over
17,000-fold for these inhibitors.
The less potent compounds can be viewed as forming 2 classes
of NS5A inhibitors with BMS-407 referred to as the CORE, derived
from the biphenyl series on which DCV is based and BMS-556
referred to as the CAP representing a “half” of NS5A symmetrical
inhibitors. These compound elements are active and independent
pharmacophores present in the fully symmetrical compounds,
with the covalent linkage in BMS-411 and related compounds
such as DCV, cementing both elements together. To probe each
pharmacophore's interaction with the NS5A protein, BMS-556
(cap) or BMS-407(core) were used to select resistance at ∼5-X
EC50 in the presence of G418. Following plating of wild-type
replicon cells in the presence of inhibitors with G418, colonies of
resistant cells emerged which were treated subsequently with
increasing concentrations of the respective inhibitors, up to 10 μM.
The population of selected cells was characterized for inhibitor
sensitivity (Table 1, section A). The selected cells demonstrated
resistance to the analogs used for selection as well as to the fully
symmetrical inhibitor. The speciﬁcity of resistance toward NS5A
was demonstrated by titration with NS3 and NS5B inhibitors,
which retained similar potency on both the wild-type and selected
cells (data not shown). As shown in Table 1 section A, replicon
cells selected with the cap-containing molecule BMS-556 show
greater resistance to the cap-selected cells while resistance is also
detected for the other inhibitors. Replicon cells selected with the
core pharmacophore-containing inhibitor show similar levels of
resistance to the truncated inhibitors, suggesting there is a less
well-deﬁned binding interaction between the core compound and
the NS5A protein. The potency data indicates that the resistancemutations selected by the core and cap analogs are distinct from
each other, as revealed by the resistance levels of 137-fold for the
cap selections versus ∼4-fold for the core selected cells when
tested versus the fully symmetrical compound. Sequencing of the
5A region for replicon clones revealed a difference in amino acid
substitutions (Table 1, section B) that accounted for the resistance
patterns. The core compound genotype results indicate a prefer-
ence for interactions with both the L31 and the Q54 region. The
cap compound resistance data suggests that this pharmacophoric
element is interacting and affected more with the Y93 region of
the NS5A protein under the conditions used for selections. This
pattern is consistent with the hypothesis that fully symmetrical
inhibitors make contact with the NS5A protein in close proximity
to all of the amino acids L31, Q54 and Y93 within the NS5A binding
region. DCV resistance on these substitutions have been reported
to be similar (∼20-fold) conﬁrming the ability of both regions to be
capable of interaction within compounds containing both ele-
ments (Fridell et al., 2010).Discussion
The NS5A inhibitors described in this report were used in a
series of experiments to probe and characterize the manner by
which these compounds interact with the NS5A protein. The study
of the binding and interactions of the inhibitors could only be
efﬁciently accomplished by the application of these inhibitors to
HCV replicon cells, since numerous attempts using puriﬁed NS5A
proteins were unsuccessful at detecting binding with the same
level of speciﬁcity. The use of HCV replicon cells to characterize
compound binding provided biochemical data indicating that
NS5A inhibitors are tightly and speciﬁcally bound non-covalently
to the NS5A protein. The use of SDS and heating was required to
preferentially remove the NS5A protein from a mono-biotinylated
compound compared to a ﬂourescein-streptavidin control empha-
sizing the high binding afﬁnity possible with this compound
series. The stability of the 5A-compound complex in the numerous
elution conditions allowed additional manipulations and experi-
ments to be performed probing the interactions of inhibitors
with the 5A protein that would have been much more difﬁcult
to ascertain otherwise. The speciﬁcity of these inhibitors was
D.R. O'Boyle II et al. / Virology 444 (2013) 343–354350further conﬁrmed by the successful cross-linking and isolation of a
compound-peptide fragment corresponding to the amino-terminal
region of the NS5A protein using intact HCV replicon cells. Comple-
menting and extending the compound binding studies was the
detection of an NS5A dimer using the bis-azide derivative. These
results demonstrated that cross-linking of NS5A proteins is compatible
with a stoichiometry of at least 1 compound to 2 NS5A proteins and is
in agreement with other studies looking at the propensity of NS5A to
form dimers in intact cells (Bhattacharya et al., 2012). Additional
binding modes are possible, as reﬂected by the 2 crystal forms of NS5A
(Love et al., 2009; Tellinghuisen et al., 2005) and likely given the
potential for NS5A to be conformationally ﬂexible to allow each
domain of the protein to fulﬁll its multifaceted role. Based upon the
available data from our group as well as others, direct binding across a
dimer interface is the preferred hypothesizedmodality and the current
model used for explaining the binding results with symmetrical
compounds. The detection of higher molecular weight NS5A cross-
linked multimers may suggest that additional compound–protein
interactions are occurring, although the amount of monomeric 5 A
species present indicates that, similar to the dimer, these are in a low
minority. The bis-azide data suggests speciﬁc interactions since the
application of cell-permeable chemical cross-linkers does not yield
precise NS5A reactive bands indicative of discrete N¼2, 3 etc. but a
smear of reactivity indicating non-speciﬁc cross-linking is occurring
(unpublished observations). The NS5B polymerase and the NS3
protease protein comparators used in several of the binding studies
did not reveal interactions that were detected with NS5A in this
compound series, evenwhen present in excess, further conﬁrming the
speciﬁcities of the inhibitors for NS5A.
HCV replicon resistance selection used to complement the com-
pound binding studies demonstrated the ability to separate mutations
in the NS5A protein to areas between amino acids 30 and 93 while the
resistant replicons remained sensitive to inhibitors targeting the NS3
protease or the NS5B polymerase. Further genetic evidence implicating
NS5A domain1 protein interactions with NS5A replication complex
inhibitors has been demonstrated for different HCV genotypes, con-
ﬁrming the speciﬁcity of these inhibitors for the NS5A protein (Lemm
et al., 2010; Gao et al., 2008; Scheel et al., 2011). Additionally,
resistance selection and characterization of resistance substitutions
have been reported for analogs of the inhibitors used in this study
including DCV (Lemm et al., 2010; Fridell et al., 2010) with similar
results. Although the selection using less potent inhibitors readily
generated separate areas of changes, the conditions used for selection
as well as polymorphisms present in the replicon cell population may
inﬂuence which mutations arise (Sun et al., 2012). The presence of low
levels (∼1%) of known 5A resistance mutations have been observed
(unpublished observations) and may also inﬂuence mutation genera-
tion, especially with less potent inhibitors. The most potent compound
characterized in this series was a symmetrical inhibitor similar to DCV.
The stereochemistry of this compound and the interactions with the
NS5A dimer are hypothesized to represent distinct inhibitory pharma-
cophoric elements designated as the cap and core moieties. The
inherent inhibitory potency of the fully symmetrical compound
allowed for signiﬁcant antiviral activity to be retained by pharmaco-
phore fragments resulting in inhibitory activity being readily dis-
cerned. Fragmentation of small molecules into more basic binding
elements has been demonstrated as a useful method to screen for
compounds that bind to targets of interest (Erlanson, 2012; Everts,
2008) and may be able to provide a starting point for additional NS5A
compound optimizations. The use of genotype 1b cells likely assisted
in this endeavor since BMS-671 can bind to not only the mutant Y93H
gt1b cell line, as demonstrated in Fig. 1 but also to the gt1a NS5A
protein but, like the Y93H mutant, is not inhibitory (unpublished
observations). Thus, as stated previously, binding appears necessary
but not sufﬁcient for inhibition, requiring additional function(s) that
further structural modiﬁcations can overcome, exempliﬁed by thosepresent in symmetrical and non-symmetrical higher molecular weight
compounds (Fridell et al., 2010; Gao et al., 2011; Lawitz et al., 2012;
Christopher O’Brien and Agresti, 2012). The ability of small molecules
to bind speciﬁcally to NS5Awith no detectable consequence has utility
in combination with other NS5A targeting compounds and will be the
focus of additional disclosure in the future (Bristol-Myers Squibb,
2012b; Gao et al., 2013).
The use of in vitro NS5A assays have recently reported negative
results using a dimer interference assay with BMS-052 (DCV, Lim
et al., 2012). The absence of demonstrable speciﬁc binding of the
compounds to puriﬁed protein or crude cell extracts negated our
ability for direct biochemical characterizations performed with
deﬁned components, such as RNA binding interactions, as demon-
strated by Huang et al. and others (Huang et al., 2005; Lim et al.,
2012). Disruptions of replication complexes in association with
membranes as evidenced with immunostaining by DCV in intact
cells have been reported, providing the ﬁrst evidence of a
mechanism of action related to compound addition to intact cells
(Targett-Adams et al., 2011; Lee et al., 2011). This may suggest, and
is reasonable with the model to be presented, that the compounds
initially interact with a NS5A protein form that is only present
transiently, requiring the compound to be present prior to transla-
tion/folding and with subsequent binding to an intermediate
(s) prior to polyprotein processing. This is reminiscent of the
requirement for an intact polyprotein consisting of NS3 to 5A for
5A hyperphosphorylation to occur (Neddermann et al., 1999) and
is in agreement with studies performed by Fridell et al. who
hypothesize that hyperphosphorylation is possibly attributable to
unique conformations of NS5A (Fridell et al., 2011a). Other
possibilities that might explain the lack of in vitro compound
binding could be technical in nature, with the protein requiring
cofactors or conditions that are not duplicated in our attempts to
assess drug–target interactions. These possibilities remain under
active investigation.
The initial thiazolidinones lead series of NS5A inhibitors were
the basis for the synthesis of the compounds presented here
(Romine et al., 2011). Using a multiplexed cell-based screen, the
initial lead BMS-858 (Lemm et al., 2010) was used as a platform for
further modiﬁcation and SAR studies which resulted in the
evolution of NS5A inhibitors to compounds described in this
report and elsewhere (Belda and Targett-Adams, 2012). The use
of the thiazolidinone lead compounds to generate resistant repli-
cons has been shown to result in the appearance of mutations
located at amino acids 31, 54 and 93 of the NS5A protein (Lemm
et al., 2010), indicating the relatedness to the more sophisticated
and potent symmetrical compounds. However, it has since been
established that select thiazolidinones have the potential to
undergo oxidation in DMSO solution and replicon media forming
a reactive radical intermediate that can either react with molecular
oxygen or dimerize to a more potent symmetrical compound
(Lemm et al., 2010, 2011; Gao et al., 2009; Romine et al., 2011).
The compounds presented in this report are devoid of the
thiazolidinone ring and are known to be chemically stable. There-
fore the resistance data generated by the cap and core components
presented herein reﬂect the activity of the parent molecules.
The smaller pharmacophoric elements embedded in the larger
symmetrical molecules can be inhibitory by themselves although
at a signiﬁcant cost in potency, suggesting the importance of
uniting the elements into a single molecule for optimal inhibition
of NS5A activity. The region of interaction corresponds to the area
implicated in dimer formation of NS5A documented in crystal
structures (Love et al., 2009; Tellinghuisen et al., 2005) and
recently demonstrated in vitro (Lim et al., 2012). A symmetrical
molecule, or one that has the necessary functionality to comple-
ment the target, can be envisaged to interact with a region
between the monomers, binding/interacting with a stoichiometry
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NS5A monomers with at least 6 amino acids in the protein (∼3 per
dimer) and likely others forming an interaction network (Fridell
et al., 2010). This suggests a possible mechanism by which the
compounds modulate a function(s) of the dimer necessary for
replication but which does not necessarily rely upon preventing
protein association into a dimeric species; indeed, the inhibitors
may promote association of NS5A into dimers (Huang et al., 2005).
This scenario can be depicted as a model of compound bound to
the NS5A protein dimer while the protein complex interacts with
the lipid monolayer (Appel et al., 2005a, 2005b; Elazar et al.,
2003). The hypothetical model presents one of the 2 solved NS5A
domain 1 crystal dimers binding to BMS-411. The compound–
protein structure containing more authentic NS5A amino acids
(aa's 25–215, Tellinghuisen et al., 2005) was used but both dimeric
forms could be biologically relevant with higher-order polymeric
structures possible by combining the two conformations (Love
et al., 2009). The model is captured in Fig. 8 from the perspective
of looking upward from the membrane into the 5A protein and
through to the NS5A putative RNA binding site. This model, which
best agrees with the data, was developed using QUANTA (Quanta
Modeling Environment, 2006) and the coordinates of the Domain
1 dimer from the Tellinghuisen et al. X-ray structure (Tellinghuisen
et al., 2005) and the NMR structure of the amino terminal alpha
helix by Penin et al. (2004). The model depicts the region(s) of
interaction with the fully symmetrical compound with the amino
acids implicated in compound resistance highlighted in yellow.
The model shows BMS-411 bound across the dimer interface with
the CAPS proximal to Y93 and the CORE located under L31. Q54 sets
near the ends of BMS-411 and is in contact with L28 of the amino
terminal alpha helices. The Q54 interaction with the N-terminal
helix may assist in positioning L31 over the CORE. While this
model is compatible with the observed potency differences
between genotypes and the isolated resistance mutations, a more
deﬁnitive understanding of the drug–target binding mode will
require solution of NS5A or NS5A dimer with compound bound.
NS5A has been demonstrated to have essential functions in
replication, viral nucleic acid encapsidation and host cell modulation,Fig. 8. Hypothetical model of BMS-411 interaction with NS5A protein dimer
presents one possible NS5A replication complex inhibitor binding mode. The
model was constructed using the NS5A Domain 1 crystal structure (1ZH1) and
amino terminal alpha helical NMR structure (1R7C). The coordinates were incor-
porated into the model and the BMS-411 compound. The residues 32–35 were
modeled in by hand to enforce symmetry using QUANTA (Quanta Modeling
Environment, 2006). The smaller model depicts the region(s) of interaction with
the fully symmetrical compound with the amino acids implicated in compound
resistance highlighted with yellow carbon atoms (ball and stick). The larger model
shows BMS-411 bound across the dimer interface with the CAPS proximal to Y93
amino acids and the CORE lying under the L31 residues. The Q54 residues set near
the ends of BMS-411 and are in contact with L28 of the amino terminal alpha
helices. The Q54 interaction with the N-terminal helix may assist in positioning L31
over the CORE. Colors in smaller model: NS5A domain I residues 36–198 are blue
and green and respective N-terminal regions 1–20 and 31–35 are mauve and
bisque; The photoafﬁnity labeled fragment, residues 21–30, are purple; the carbon
atoms of BMS-411 are gray, all other atoms are oxygen: red, nitrogen: dark blue,
and polar hydrogen: white. The image was generated using PYMOL (PyMOL).all of which are important in the viral replication cycle (Scheel et al.,
2011; Tellinghuisen et al., 2007, 2008b; Huang et al., 2007; Fridell
et al., 2011b). Thus, the NS5A inhibitors may perturb multiple
interactions, including membrane associations (Targett-Adams et al.,
2011; Lee et al., 2011; Fridell et al., 2013) or egress from the cells
(Guedj et al., 2013),whose sum reﬂects the high level of potency
achieved with this chemotype. Compound binding to the NS5A dimer
could cause disruption of the protein–lipid complex resulting in
dominant and non-permissive replication. The model suggests that
interactions may be transmitted via the lipid bilayer by modulation of
the alpha-helical interactions that have been shown to be essential
for NS5A function (Elazar et al., 2003). The recent description of the
association of NS5A with TBC1D20 and Rab1 provides membrane-
associated proteins whose functions may also be modulated by the
NS5A compound series (Nevo-Yassaf et al., 2012). The abundance of
cellular proteins interacting with the NS5A protein could also be
attenuated by interaction with this class of inhibitor, providing
opportunity for further study.
The NS5A protein has been estimated to be present at a
concentration of ∼70 nM in the HCV replicon cell line that was used
for these studies (data not shown) and has been estimated by other
groups to be present at 20,000–40,000 copies per replication com-
plex (Quinkert et al., 2005). The ability to inhibit the replicon with
picomolar amounts of compound suggests that an inhibitory
mechanism is ampliﬁed in the cells since the ratio of protein to
compound is estimated to be 41000 fold. This has been documented
for other inhibitors such as cyclosporine that target a minority of
cyclophilin proteins while exerting potent biological effects due to the
protein–inhibitor complex being a dominant and active inhibitor of
calcineurin (Halloran, 2001). This suggests that the NS5A protein,
either as a dimer or higher polymeric form, may bind compound in a
fashion that allows communication with other HCV replication
centers in the cell, either directly or indirectly, to cause replication
incompetency. Further work is required to more fully deﬁne the
mechanism(s) by which these unique compounds function.
Precisely how the compounds inhibit HCV replication remains a
complex question to answer but it is clear that the HCV NS5A protein
represents a crucial link to many required viral functions and
presents an excellent clinical target for small molecule antiviral
intervention. The design of daclatasvir was guided, in part, by the
results obtained with the compounds reported herein. Daclatasvir is
currently undergoing Phase 3 clinical testing (Lok et al., 2012;
Chayama et al., 2012; Sun et al., 2012), providing impetus for further
mechanism of action studies. The complex interactions that occur
between symmetrical inhibitors and the amino-terminal of NS5A
generate speciﬁc and tight binding interactions that lead to potent
inhibition of HCV replicon replication.
The characterizations and model presented here based on the
compound classes described in this report provide a number of
tools and observations to use in further deﬁning a mechanism
(s) amenable to future experimentation as well as possible
application to other related viruses that contain an NS5A analog.Experimental procedures
Cell culture and compounds
Huh-7 cells were grown in Dulbecco's modiﬁed Eagle medium
(DMEM) with 100 U/ml penicillin/streptomycin and 10% fetal
bovine serum (FBS). HCV replicon cell lines were isolated as
previously described (Lemm et al., 2005, 2010; Krieger et al., 2001)
andmaintained in media that also contained 0.3–1.0 mg/ml Geneticin
(G418). Huh-7 cells cured of a Con1 replicon were generated as
previously described (Lemm et al., 2005) and propagated in DMEM
with penicillin/streptomycin and 10% FBS.
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The compounds used in this study were prepared at Bristol-
Myers Squibb. Detailed synthesis of the compound class has been
presented and will be the subject of future publications (Bristol-
Myers Squibb, 2004, 2007, 2008a, 2008b, 2008c, 2012a; Gao et al.,
2010; Romine et al., 2011; St. Laurent et al., 2012, 2013; Belda and
Targett-Adams, 2012).
Afﬁnity puriﬁcation of NS5A protein
For use as afﬁnity reagents, compounds (typically 6 μM, unless
noted differently) were added to separate T-175 ﬂasks of HCV gt1b
(Con-1) or NS5A gt1b mutant (Y93H) replicon cells (∼80% conﬂuent,
previously described (Fridell et al., 2010) and incubated under normal
growth conditions for ∼18 h. Cells were removed with EDTA-free Cell
Dissociation Buffer (Invitrogen Corporation, Carlsbad, CA), centrifuged
(4000g, room temperature) and resuspended in ice cold NP-40 lysis
buffer [50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 0.1% NP-
40, 1 Complete Protease Inhibitor Cocktail (Roche Applied Science,
Indianapolis, IN)]. After 15 min at 4 1C, non-soluble cell particulates
were removed by centrifugation (1500g, 10 min, 4 1C). A portion of
the supernatant was saved as an input control for immunoblot
analysis (see below) and the remainder was mixed with
streptavidin-agarose beads (typically 30–100 μl, Sigma Corporation,
St. Louis, MO) and incubated with gentle rocking at 4 1C. Beads were
pelleted by brief centrifugation, washed 5 times (500 μl NP-40 lysis
buffer), resuspended in SDS gel loading buffer, and heated for 3 min
at 100 1C. (Heating and elution from afﬁnity matrices was varied for
some experiments as described in the text.) After a brief spin
(14,000g 5 min) supernatants were electrophoresed on 7.5% Criterion
gels (Bio-Rad Laboratories, Hercules, CA) following the manufacturer's
recommended procedure.
To compare the binding afﬁnity of the 5A-protein/compound
complex to the Streptavidin–Biotin interaction, biotinylated ﬂour-
escein (Sigma #B9431) was used with detection of ﬂuorescence in
a Cytoﬂour 4000 instrument (Excite¼485, Emission¼530). Beads
(streptavidin beads mixed with lysates or mixed with biotinylated
ﬂourescein) were washed extensively (∼10 times) with binding
buffer at room temperature prior to elution to reduce non-
speciﬁcally bound materials. After the washes, SDS–sample buffer
was added to an equal volume of beads (∼100 μL) which were then
incubated at temperatures of 70 1C for several elutions followed by
100 1C for several elutions (5 min each). Following incubation the
beads/SDS–sample buffer was mixed, brieﬂy centrifuged and
supernatants removed for analysis. For immunoblot analysis,
proteins were transferred to nitrocellulose (Towbin et al., 1979),
blocked in 5% fat free milk in Tris buffered saline (Biorad#170-
6435) and analyzed by probing with combinations of primary
polyclonal rabbit antibodies directed at HCV NS5A, NS5B or NS3
(used/made/puriﬁed in-house) or anti-NS3 #ab18664 (monoclo-
nal, Abcam), anti-NS5B #ab35586 (rabbit polyclonal, Abcam),
rabbit anti-mouse HRP-conjugated secondary #ab6728-1 (Abcam),
goat anti-rabbit HRP-conjugated secondary antibody (Biorad#170-
6515) or with a biotin-HRP antibody (Sigma#BN-34). Antibody
complexes were detected by chemiluminescence with a Western
Lightning Chemiluminescence Reagent Plus kit (PerkinElmer, Wal-
tham, MA) following manufacturer's instructions. Densitometry of
NS5A speciﬁc bands was performed using exposed ﬁlm and a
Molecular Devices Storm detector (#860) with comparison to
protein standards according to manufacturer's directions.
FLAG tagging of HCV replicon
A FLAG epitope tag was introduced into NS5A in the Con1 1b
replicon clone with the Quick Change Mutagenesis kit (StratageneCorporation, La Jolla, CA) following manufacturer's instructions.
The mutagenic oligos were (+) 5′-ACTACCCGTCATGACTACAAG-
GACGATGACGACA AAGAGGCCAACCT-3′ and () 5′-AGGTTGG-
CCTGTTTGTCGTCATCGTCCTTGTA GTCATGACGGGTAGT-3′. The seq-
uence of the modiﬁed clone was veriﬁed by sequence analysis. A
replicon cell line containing a FLAG-tagged NS5A protein was
selected as described above (O’Boyle et al., 2005; Lemm et al.,
2010; Gao et al., 2004).
Selection of resistant replicons
Selection of resistant replicon cells was performed by growing HCV
replicon cells in media containing compounds at increasing concen-
trations up to 10 mM ﬁnal. Brieﬂy, media containing compound (∼5X –
EC50) was added to monolayers of HCV 1b-377-neo replicon cells at
∼25% conﬂuence in the presence of 0.5 mg/mL G418 in a T25 tissue
culture ﬂask. The cells were split 1:10 upon conﬂuency; selection of
cells with BMS-556 and BMS-407 was changed after passage 6 to
10 μM until passage 17. Replicon cells maintained in the presence of
DMSOwere used as a control. After 5–6weeks, control DMSO-selected
replicon cells and compound-selected cells were expanded for testing
for compound sensitivity using the HCV replicon FRET assay and
processed for RT-PCR and topo cloning.
RT-PCR and sequencing
Total RNA was isolated from gt1b (Con 1) HCV replicon cells using
the Qiagen RNAeasy kit (#74104) as described by the manufacturer.
Typically, a T25 ﬂask at ∼80% conﬂuency was used for total RNA
isolation. Total RNAwas processed into cDNA using random hexamers
followed by HCV speciﬁc forward primer (5′-CCAGGGGAG-
GGGGCTGTGCAGTGGATG) and reverse primer (5′-CATTGATGGG-
CAGCTTGGTTTCCTC). The resulting PCR product containing the NS5A
region was processed using Qiagen PCR clean-up (#28104) kit. The
DNA product band was gel puriﬁed and the DNA bands Topo cloned
(pCR 2.1 TOPO vector, Invitrogen) according to manufacturer's direc-
tions. Individual DNA clones were picked, puriﬁed (Qiaprep Spin
Miniprep kit #27106) and sent for automated ﬂuorescence based
sequencing. Sequencing data was processed and assembled using
Sequencher (Gene Codes Corp., Ann Arbor, MI) DNA analysis program.
Fluorescent resonance energy transfer assay for HCV inhibitors (HCV
FRET-assay)
The ﬂuorescence resonance energy transfer assay (FRET) assay
was performed as previously described (O’Boyle et al., 2005) for
compound evaluations. Brieﬂy, following titration of compounds and
72 h incubation in assay plates at 37 1C, the plates were washed with
phosphate-buffered saline and then used for FRET assay by the
addition of 30 mL of the FRET peptide assay reagent per well. The
assay reagent consisted of 1 -luciferase cell culture lysis buffer
(Promega #E153A), 150 mM NaCl and 20 mM FRET peptide. The plate
containing assay reagent was then read in a kinetic mode in a
Cytoﬂour 4000 instrument which had been set to 340 nm excite/
490 nm emission, automatic mode for 20 cycles. EC50 values were
calculated as the concentration of compound which caused a 50%
reduction in HCV FRET activity versus a DMSO control.
Crosslinking, Immunoprecipitations and peptide identiﬁcation
To detect binding using the radiolabeled inhibitor, BMS-194,
the protocol for use of BMS-671 as an afﬁnity ligand was adapted
with the following modiﬁcations: (i) HCV 1b replicon cells expres-
sing FLAG-tagged NS5A were used. (ii) During the crosslinking
step, cells were overlaid with 1.5 mL of cold PBS, and exposed to
UV light in a UV 2400 Stratalinker (Stratagene Corporation, La
D.R. O'Boyle II et al. / Virology 444 (2013) 343–354 353Jolla, CA) for 5 min. (iii) FLAG antibody-conjugated beads (#F2426,
Sigma Corporation, St. Louis, MO) were incubated with the cell
lysates for NS5A isolation, or immobilized protein-G beads (IP-50,
Sigma Corporation, St. Louis, MO) pre-absorbed with HCV NS3
antibody were used for NS3 isolation. (iv) After detection of
proteins, the membrane blot was sprayed with EN3HANCE (Perki-
nElmer, Waltham, MA) and exposed to Kodak BioMax MS ﬁlm. A
Kodak BioMax TranScreen was used according to manufacturer's
instruction to improve the exposure efﬁciency.
An inhibitor containing both a biotin and a photo-reactive aryl
azide moiety BMS-350 was used to determine the NS5A interac-
tion site while a bis-azide homolog (BMS-351) was used to
determine the ability to detect cross-linked NS5A dimers. The
compound addition, UV crosslinking, and cell lysate preparation
were carried out as described above for NS5A interaction site
determination. To isolate NS5A at μg levels for NS5A interaction
site determination, 2 mL of anti-FLAG M2 beads (Sigma Corpora-
tion, St. Louis, MO) were incubated with cell lysates collected from
98 culture dishes (175 cm2), and the lysate bead mixture was
loaded on a column (110 cm). After washing with 20 column
volumes of wash buffer, the NS5A was eluted with 6 mL of elution
buffer (100 mM Glycine [pH 2.0], 2 mM PMSF, 0.1% NP-40). NS5A-
containing fractions were concentrated by centrifugation using an
Amico Ultra-4 microconcentrator, and fractionated by SDS-PAGE.
Proteins were stained with Coomassie Blue (BioRad Laboratories,
Hercules, CA), and the NS5A band (identiﬁed by alignment to
recombinant NS5A) was sliced from the gel. Trypsin digestion,
accompanied by TCEP and IAA modiﬁcation of cysteine residues,
was performed with an In-Gel Tryptic Digestion Kit (Pierce, Rock-
ford, IL) following the manufacturer's instructions. The digested
peptide mixture was incubated with monomeric avidin agarose
beads (#20227, Pierce, Rockford, IL) according to manufacturer's
instructions to purify BMS-350-bound peptide fragment(s). The
bound peptide fragments were subsequently eluted with biotin
(1 mg/mL) and four fractions (25 μL each fraction) were collected.
To increase the elution efﬁciency, beads were incubated in elution
buffer for 20 min at room temperature prior to collecting each
fraction. The eluted peptide fragment(s) were analyzed for mass
by Matrix Assisted Laser Desorption Ionization–Mass Spectro-
metry (MALDI/MS). Prior to MALDI/MS analysis, samples (20 μL)
were further puriﬁed using a P10 ZipTip (Millipore, Milford, MA),
and mixed with an equal volume of the matrix α-cyano-4-
hydroxycinnamic acid (10 mg/mL in 50% acetonitrile/0.1% TFA).
MALDI/MS was performed on a vMALDI-LTQ mass spectrometer
(Thermo-Fischer, San-Jose, CA) with the operating laser power at
30 arbitrary units. Data were acquired in proﬁle mode across the
400–4000m/z scan range. All solvents used were HPLC grade or
higher.
To investigate the potential of NS5A to form dimers, BMS-351
or control compounds were added to 10 conﬂuent T-175 ﬂasks
at 6 mM ﬁnal and allowed to incubate for ∼18 h. The cells were
then washed with cold PBS and the cells collected after exposure
to cell dissociation buffer (Gibco #13151-014) pelleted and
resuspended in PBS with protease inhibitors (Roche Applied
Science, Indianapolis, IN). The resuspended cells (5 mL in cold
PBS) were placed onto a 100 mm dish and cross-linked as
described above using the Stratalinker. The cells were then
pelleted and resuspended in 4 mL of cold NP-40 lysis buffer
with 0.1% Deoxycholate (NP-40-deoxy) for 10 min, spun at
3000 rpm for 10 min, and the supernatants collected for either
additional FLAG enrichment or used for SDS-PAGE with coo-
massie staining and western analysis. FLAG enrichment relied
upon batch binding to M2 beads followed by extensive washing
with NP-40-deoxy buffer with Protease Inhibitors, with a ﬁnal
wash in PBS followed by elution with 3X-FLAG peptide (0.15 mg/
mL, Sigma#F4799) in PBS.Acknowledgments
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